Rasburicase: A new approach for preventing and/or treating tumor lysis syndrome

Current Pharmaceutical Design

Volumn 11, Issue 32, 2005, Pages 4177-4185

  Bessmertny, Olga ^a   Robitaille, Lauren M ^a   Cairo, Mitchell S ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Allopurinol; Child; Malignancy; Rasburicase; Recombinant urate oxidase; Tumor lysis syndrome; Uric acid

Indexed keywords

ALLOPURINOL; ALPHA INTERFERON; CORTICOSTEROID; CYTOTOXIC AGENT; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; IMATINIB; METHOTREXATE; MONOCLONAL ANTIBODY; RASBURICASE; RITUXIMAB; TAMOXIFEN; THALIDOMIDE; URATE OXIDASE; URIC ACID; URICOZYME;

ALKALINIZATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG USE; FEVER; HEADACHE; HIGH RISK PATIENT; HUMAN; HYDRATION; HYPERPHOSPHATEMIA; HYPERURICEMIA; KIDNEY FAILURE; LIVER TOXICITY; MAXIMUM PERMISSIBLE DOSE; METABOLIC DISORDER; NAUSEA; OBESITY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TUMOR LYSIS SYNDROME; VOMITING;

CLINICAL TRIALS; ECONOMICS, PHARMACEUTICAL; HUMANS; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 27944487908     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774913291     Document Type: Review

References (28)

1. National Cancer Institute Common Terminology Criteria for Adverse Events v.3 (CTCAE) (http://ctep.cancer.gov/reporting/ctc.html).
2. Cairo MS, Bishop N. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127: 3-11.
3. Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003; 82: 160-5.
4. Yeldandi AV, Yeldandi V, Kumar S, Murthy CV, Wang XD, Alvares K, et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene 1991; 109: 281-4.
5. Cairo MS, Arikian S, Casciano S, Stern L, Morris E, Yaish H, et al. Uric acid (UA) level is a significant and independent prognostic factor in the development of tumor lysis syndrome (TLS) and renal complications in patients with hematologic malignancies admitted for chemotherapy. Blood 2002 (abstract); 100: 284b.
6. Bell T, Candrilli S, Irish W, Morris E, Goldman S, Cairo MS. Medical resource use and costs associated with renal complications among patients with hematologic malignancies. Blood 2002 (abstract); 100: 221a.
7. Altman KI, Smull K, Barron ES. A new method for the preparation of uricase and the effect of uricase on the blood uric acid levels of the chicken. Arch Biochem 1949; 21: 158-65.
8. Ribeiro RC, Pui CH. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin Lymphoma 2003; 3: 225-32.
9. Legoux R, Delpech B, Dumont X, Guillemot JC, Ramond P, Shire D, et al. Cloning and expression in Escherichia coli of the gene encoding Aspergillus flavus urate oxidase. J Biol Chem 1992; 267: 8565-70.
10. Kissel P, Lamarche M, Royer R. Modification of uricaemia and the excretion of uric acid nitrogen by an enzyme of fungal origin. Nature 1968; 217: 72-4.
11. Masera G, Jankovic M, Zurlo MG, Locasciulli A, Rossi MR, Uderzo C, et al. Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 1982; 100: 152-5.
12. Pui CH, Relling MV, Lascombes F, Harrison PL, Struxiano A, Mondesir JM, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997; 11: 1813-6.
13. Elitek. Prescribing information. Sanofi-Synthelabo, New York; July 2002.
14. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19: 697-704.
15. Coiffier B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet A, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de 1'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21: 4402-6.
16. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97: 2998-3003.
17. Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001; 15: 1505-9.
18. Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003; 98: 1048-54.
19. Jacob F, Drelon E, Neefe J, Lascombes F. New drug to lower uric acid levels in healthy volunteers. Advances on prevention and control of hyperuricemia in malignancies. Proc Am Assoc Cancer Res 1996 (abstract); 37: 214.
20. Hummel M, Buchheidt D, Reiter S, Bergmann J, Hofheinz R, Hehlmann R. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia 2003; 17: 2542-4.
21. Lee AC, Li CH, So KT, Chan R. Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003; 37: 1614-7.
22. McGettigan C, Morgan T, Myhand R, Dutcher B, Waselenko J, Buda-Okreglak E. Rasburicase causing rapid decline of uric acid and resolution of acute renal failure in a patient with refractory Burkitt's leukemia and severe tumor lysis syndrome (TLS). Blood 2003 (abstract); 102: 4770.
23. Navolanic PM, Pui CH, Larson RA, Bishop MR, Pearce TE, Cairo MS, et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia 2003; 17: 499-514.
24. Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H, et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer 2003; 11: 249-57.
25. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Design 2005; 11(32): 4161-75.
26. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Design 2004; 10(1): 39-49.
27. Moehler TM, Hillengass J, Goldschmidt H, Ho AD. Antiangiogenic therapy in hematologic malignancies. Curr Pharm Design 2004; 10(11): 1221-34.
28. Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Design 2003; 9(14): 1107-13.